Table 1.
Published evidence of long-term treatment with Ozurdex® in retinal vein occlusion
| Ref. no. and first author (year of publication) | n (eyes) O: Dex C: Control | n (patients) | Study design R, P, PR, NR | Duration of follow-up period (months) | Number of patients with ME due to: C, B | Duration of ME before therapy (months) | Pre-treatment (N, A, T, L, O) | |
| [17] Coscas (2014) | O: 128 | 128 | R | ≥6 | C: 58 B: 70 |
<6 in 62 patients |
A: 39 L: 9 A + L: 8 O: 10 |
|
| [18] Mayer (2013) | Group 1: O: 38 Group 2: 3x bevacizumab followed by O: 26 |
64 | P / NR | 12 | Group 1: C: 22 / B: 16 Group 2: C: 14 / B: 12 |
max. 4 | Group 1: N Group 2: A: 26 |
|
| [22] Haller (2011) | 1256 O (0.35 mg): 412 O (0.7 mg): 421 Sham: 423 |
1256 | PR | 12 | n.r | >1.2 | N | |
| [24] Joshi (2013) | O: 51 | 49 | R | ≥12 | C: 28 / B: 23 | C: 5.3 B: 5.5 |
C: N B: L: 6 |
|
| [27] Bezatis (2013) | O: 102 | 102 | R | 6 | C: 48 B: 54 |
C: 10.6 B: 6 |
n.r. | |
| [29] Capone (2014) | O: 289 | 289 | R | ≥6 | B:157 C:132 |
All: 18.4 B: 20.1 C: 16.4 |
A: 205 L: 112 N: 39 |
|
| [31] Querques (2013) | O: 33 | 32 | R | ≥6 | C: 26 / B: 7 | All: 16.9 C: 17.1 B: 16 |
A: 18 A + L: 2 |
|
| [32] Querques (2014) | O: 19 | 19 | P | 6 | C: 13 / B:6 | 2.3 | N | |
| [33] Schmitz (2014) | O: 324 | 342 | R | 8 | n.r. | n.r. | n.r. | |
| [35] Singer (2012) | O: 34 | 33 | P | 6 | C: 12 / B: 22 | n.r. | A: 34 | |
| [44] Ozkok | O: 35 T: 39 O: 30 / |
74 | R | ≥12 | B: O: 18, T: 20 C: O: 17, T: 19 |
n.r. | A: 74 | |
| [45] Gado (2014) | Bevacizumab 30 | 60 | PR | 6 | C = 60 | n.r. | N | |
| [46] Matonti (2013) | O: 220 | 220 | R | 6 | C: 89 B: 131 |
7.1 | N | |
| Ref. no. and first Author (year of publication) |
n (eyes) O: Dex C: Control |
n(patients) | BCVA baseline (logMAR) | BCVA 90 days (logMAR) | CRT (μm) baseline | CRT (μm) 90 days | IOP max (mmHg), n = eyes | n (no. of eyes re-treated); no. of inj.; re-treatment interval (months) |
| [17] Coscas (2014) | O: 128 | 128 | All patients: 0.42 BRVO: 0.44 CRVO: 0.41 |
n.r. | BRVO: 507.5 ± 158 CRVO: 629.4 ± 191.2 |
BRVO: 292.9 CRVO: 274.3 |
IOP >25 mm Hg n = 9 |
n = 128; −; 5.9 following the 1st inj. 8.7 following the 2nd |
| [18] Mayer (2013) | Group 1: O: 38 Group 2: 3x Bevaci-zumab followed by O: 26 |
64 | Group 1: CRVO: 1.55 BRVO: 1.5 Group 2: CRVO: 1.7 BRVO: 1.45 |
n.r. | Group 1: CRVO: 604.4 ± 230.5 BRVO: 500.5 ± 106 Group 2: CRVO: 601.1 ± 252.5 BRVO: 469.8 ± 151.7 |
n.r. | Group 1: CRVO: n = 9 BRVO: n = 6 Group 2: CRVO: n = 6 BRVO: n = 5 |
Group 1: CRVO: n = 22; 2.4; 3.8 BRVO: n = 16; 1.8; 3.5 Group 2: CRVO: n = 14; 2.4; 3.2 BRVO: n = 12; 2; 3.7 |
| [22] Haller (2011) | 1256 O (0.35 mg): 412 O(0.7 mg): 421 Sham group: 423 |
1256 | n.r. | n.r. | n.r. | n.r. | O (0.7 mg): n = 53 after 1st DEX inj. n = 65 after 2nd DEX inj. |
O (0.35 mg/0.7 mg): 329; 2; 6 O (0.7 mg/0.7 mg): 341; 2; 6 |
| [24] Joshi (2013) | O: 51 | 49 | BRVO: 0.8 CRVO: 1.0 |
n.r. | BRVO: 451 ± 104 CRVO: 480 ± 174 |
BRVO: 280 * CRVO: 320 * |
>25 mm Hg, n = 14 |
n = 19; 2; BRVO: 4.3 CRVO: 4.5 |
| [27] Bezatis (2013) | O: 102 | 102 | BRVO: 0.6 CRVO: 0.7 |
BRVO: 0.4 CRVO: 0.6 |
BRVO: 559 ± 209 CRVO: 740 ± 351 |
BRVO: 369 ± 126 CRVO: 455 ± 251 |
No ocular hyper-tension | BRVO n = 22; −; 4.4 CRVO: n = 24; −; 4.4 |
| [29] Capone (2014) | O: 289 | 289 | All patients: 1.0 BRVO: 0.9 CRVO: 1.2 |
n.r. | All patients: 438 ± 182 BRVO: 413 ± 149 CRVO: 469 ± 201 |
All patients ≦250 in 65.3 % BRVO: ≦250 in 66.0 % CRVO: ≦250 in 64.4 % |
IOP >25 mm n = 95 IOP >35 mmHg n = 27 |
n = 186; M 3.2; 5.6 |
| [31] Querques (2013) | O: 33 | 32 | 0.65 | n.r. | 636 ± 217 | n.r. | n = 12 | 1st inj.: −; 4.7; 2; − 2nd inj.: −; 5.1; 2; − |
| [32] Querques (2014) | O: 19 | 19 | 0.5 | 0.54 | 762 ± 259 | 518 ± 251 | 24.3 mmHg, n = 5 >21 mmHg |
-; −; 4.3 |
| [33] Schmitz (2014) | O: 324 | 342 | n.r. | n.r. | n.r. | n.r. |
n = 62 >35 mmHg n = 6 |
-; 1.2; − |
| [35] Singer (2012) | O: 34 | 33 | n.r. | n.r. | 513 | 269 | IOP ≥ 23 mmHg | n = 28; −;4.2 |
| [44] Ozkok | O: 35 T: 39 |
74 | BRVO: O: 0.44 T: 0.40 CRVO: O: 0.75 T: 0.71 |
n.r. | BRVO: O: 467.8 ± 125 T: 500 ± 78 CRVO: O: 518 ± 160 T: 550 ± 92 |
n.r. |
n = 6 >21 mmHg O: n = 11 T: n = 15 |
BRVO: O: n = 18; 1.4; 7 T: 20; 2.1;5 CRVO: O: 17;1.6; 6.3 T: 19; 2.6; 4.6 |
| [45] Gado (2014) | O: 30 / Bevaci-zumab 30 | 60 | O group: 0.6 Bevaci-zumab group: 0.6 |
n.r. | O group: 548.53 ± 68.67 Bevacizu mab group: 544.13 ± 48.68 |
O group: 280 Bevaciz umab group: 283 |
O group: IOP > 21 mmHg n = 6 |
O group: n = 30; 2; 4 |
| [46] Matonti (2013) | O: 220 | 220 | All patients: 1.2 CRVO: 1.3 BRVO: 1.1 |
0.9 | All patients: 641.86 ± 221.6 CRVO: 686 ± 247.1 BRVO: 612.4 ± 198.8 |
All patients: 362.5 ± 184.8 |
n.r. | n = 108; 2; 5.3 |